Amgen

Biotechnology
AMGN
$ 271 0.68
Share price
$ 145 bn
Market Cap
$ 171 bn
Enterprise Value

Carbon footprint

0.74 Ton
GHG emissions per $ 1 mln investment
0.02x the weighted average for S&P 500
FY2022
How is this calculated?
-18%
YOY change in GHG emissions
Stronger than the -0.8% weighted average for S&P 500
FY2022 vs. previous year

Primary Climate Goal

-20%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -8% weighted average for S&P 500
FY2023
How is this calculated?

Amgen aims to achieve carbon neutrality for Scope 1 + 2 by 2027


1.5°C
Amgen's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Amgen's GHG emissions (market-based) (Kt of CO2e)
Amgen's Carbon intensity (Tons per 1 USDm)

Amgen's carbon footprint

Amgen reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2022 at 127 Kt (-28 /-18.1% y-o-y). Also positively, carbon intensity was down at 4.8 t (-1.2 /-20% y-o-y).

Amgen's Scope 3 emissions grew to 3,186 Kt (+122/+4% y-o-y). The growth rate declined vs. the previous periods (CAGR +6.6% since 4Q'20).

The company is committed to achieving carbon neutrality for Scope 1 + 2 by 2027, which translates into the estimated reduction of -25 Kt per annum over the period of FY2023 - FY2027. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Amgen aims to achive carbon neutrality across its operations (Scope 1 + 2) in 2027. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.

Company environmental metrics

Show more...